Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
ABILIFY |
| Manufacturer |
|
BMS/Otsuka Partnership |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Aripiprazole 2mg, 5mg, 10mg, 15mg, 20mg, 30mg; tabs. |
| Also |
• ABILIFY DISCMELT
• ABILIFY INJECTION
• ABILIFY ORAL SOLUTION
|
| Indications |
|
Acute and maintenance treatment of manic or mixed episodes in bipolar disorder as monotherapy; or as an adjunct to lithium or valproate. Adjunct to antidepressants for major depressive disorder. |
| Children |
|
<10yrs: not recommended. 10–17yrs: Bipolar disorder: initially 2mg/day, then increase to 5mg/day after 2 days, then increase to target dose of 10mg/day after 2 days. Subsequent dose increases may be adjusted by increments of 5mg/day; max 30mg/day. Maintenance: continue at lowest dose to maintain remission; see literature. |
| Adults |
|
Tabs and soln may be interchanged on a mg–to–mg basis up to 25mg; 30mg as tablet is equivalent to 25mg oral soln. Discmelt: Dissolve on tongue; take without liquids. Bipolar disorder: initially 15mg once daily; may increase to max 30mg/day; maintenance: 15mg/day or 30mg/day (see literature for duration of therapy). Adjunct to major depressive disorder: initially 2–5mg/day; may adjust by 5mg/day increments at intervals of ≥1 week; usual range: 2–15mg/day. Reduce aripiprazole dose by at least ½ with CYP3A4 inhibitors or CYP2D6 inhibitors. Double aripiprazole dose (max 30mg/day) with CYP3A4 inducers. Adjust dose to normal range when these drugs are withdrawn. |
| Precautions |
|
Cardio- or cerebrovascular disease. Risk of hypotension, aspiration pneumonia, seizures, or diabetes (do baseline fasting blood sugar). Exposure to extreme heat. Dehydration. Reevaluate periodically. Monitor for hyperglycemia. Exclude neuroleptic malignant syndrome if fever occurs. Suicidal tendencies. Write Rx for smallest practical amount. Elderly (not for dementia-related psychosis). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Avoid alcohol. Caution with other centrally-acting drugs. Potentiates antihypertensives. Levels may be reduced by CYP3A4 inducers (eg, carbamazepine). Levels may be increased by CYP3A4 inhibitors (eg, ketoconazole) or CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Caution with drugs that interfere with temperature regulation (eg, anticholinergics). |
| Adverse Reactions |
|
Headache, anxiety, insomnia, GI upset, somnolence, akathisia, orthostatic hypotension, asthenia, blurred vision, tremor, neuroleptic malignant syndrome, tardive dyskinesia, weight gain, others. Inj: local reactions. |
| How Supplied |
Tabs 2mg—30
5mg, 10mg, 15mg, 20mg, 30mg—30, 100
Oral soln (w. dosing cup)—150mL
Discmelt—30
Single use vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
